|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.680 USD | +3.09% |
|
-6.57% | +287.88% |
| 05-20 | Exchange-Traded Funds, Equity Futures Advance Pre-Bell Wednesday Ahead of Nvidia Earnings Report | MT |
| 05-20 | ImmunityBio's Supplemental Biologics License Application for Anktiva Accepted by FDA | MT |
Business description: ImmunityBio, Inc.
Number of employees: 688
Sales by Activity: ImmunityBio, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Focused on Developing Next-Generation Therapies | 934K | 240K | 622K | 14.74M | 113M |
Geographical breakdown of sales: ImmunityBio, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 373K | 42K | 31K | 14.21M | 113M |
Europe | 561K | 198K | 591K | 531K | 278K |
Executive Committee: ImmunityBio, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Adcock
CEO | Chief Executive Officer | 57 | 30/09/2020 |
| Chief Executive Officer | 73 | 28/02/2015 | |
David Sachs
DFI | Director of Finance/CFO | 48 | 28/02/2021 |
Bruce Brown
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/2024 |
Enrique Dilone
CTO | Chief Tech/Sci/R&D Officer | 59 | 13/08/2023 |
Composition of the Board of Directors: ImmunityBio, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Wesley Clark
BRD | Director/Board Member | 80 | 31/01/2021 |
| Director/Board Member | 71 | 28/02/2021 | |
| Chairman | 73 | 30/11/2014 | |
Richard Adcock
BRD | Director/Board Member | 57 | 28/03/2021 |
Barry Simon
BRD | Director/Board Member | 61 | 31/12/2006 |
Michael Blaszyk
BRD | Director/Board Member | 73 | 30/06/2015 |
Cheryl Cohen
BRD | Director/Board Member | 60 | 31/05/2019 |
Linda Maxwell
BRD | Director/Board Member | 52 | 28/03/2021 |
Bruce Wendel
BRD | Director/Board Member | 72 | 11/12/2025 |
Company details: ImmunityBio, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.09% | -6.57% | +179.27% | +158.59% | 8.04B | |
| +0.24% | -1.54% | +52.85% | +71.85% | 53.83B | |
| -7.17% | -4.39% | +42.72% | +73.32% | 52.1B | |
| +0.80% | -6.31% | +5.62% | +417.78% | 23.48B | |
| -0.09% | -0.01% | -16.85% | -15.41% | 23.13B | |
| -5.95% | -2.58% | +29.53% | -9.47% | 19.36B | |
| -1.14% | +0.03% | +31.67% | -30.65% | 17.56B | |
| -5.16% | -7.00% | +168.44% | +314.96% | 15.2B | |
| -6.91% | -5.83% | +25.17% | +644.30% | 14.83B | |
| +0.43% | -1.03% | +25.75% | +189.74% | 14.06B | |
| Average | -2.19% | -3.02% | +54.42% | +181.50% | 24.16B | |
| Weighted average by Cap. | -2.60% | -2.50% | +44.20% | +143.64% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IBRX Stock
- Company ImmunityBio, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition